Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]
In development
Reference number: GID-TA10882
Expected publication date: TBC
The National Institute for Health and Care Excellence (NICE) has been asked to consider an evaluation of infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement ID3992. We have recently invited stakeholders to respond to a written consultation on the draft scope for this proposed evaluation.
Following a recent update from the company that market infigratinib, NICE has agreed that continuing the scoping exercise at this time would not be appropriate. As a consequence of this, the draft scope consultation has been cancelled. We apologise for any inconvenience this may cause. The scoping exercise will be rearranged for later date.
If you have any comments or concerns, please contact the Scoping Project Manager for this proposed evaluation Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk).